Using a machine-learning algorithm, researchers can predict interactions that could interfere with a drug’s effectiveness.
PHILADELPHIA -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S.
Recipients’ research focused on melanoma diagnosis, treatment response in advanced NSCLC, and bypassing common hurdles in NSCLC diagnosis and treatment
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.
